<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829569</url>
  </required_header>
  <id_info>
    <org_study_id>4.2003.169</org_study_id>
    <secondary_id>03-14463</secondary_id>
    <secondary_id>15759</secondary_id>
    <secondary_id>03/05008</secondary_id>
    <nct_id>NCT00829569</nct_id>
  </id_info>
  <brief_title>n-3 Fatty Acid Infusion and Type 2 Diabetes</brief_title>
  <official_title>Effects of Marine n-3 Fatty Acid Infusion on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Foundation for Health and Rehabilitation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this experimental study is to investigate whether an acute lipid infusion
      added marine n-3 fatty acids produces effects on insulin sensitivity in subjects with type 2
      diabetes, when compared with an acute lipid infusion without marine n-3 fatty acids.
      Furthermore other effects on intermediary metabolism are tested for.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence indicates that n-3 fatty acids exert several beneficial effects. However, the
      effects of marine n-3 fatty acids on intermediary metabolism have not been completely
      elucidated. In a previous study of a high intake of marine n-3 fatty acids during 9 wk we
      demonstrated reduced insulin sensitivity and altered proportion of carbohydrate vs. fat
      oxidation in subjects with type 2 diabetes. These results question the use of high doses of
      n-3 supplements in type 2 diabetes. It is not known to what extent such effects in type 2
      diabetes can be reproduced by intravenous administration of n-3 fatty acids and/or whether
      short term intravenous administration has other effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>n-3 fatty acid distribution</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy metabolism</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Intralipid with/without Omegaven</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lipid infusion with/without marine n-3 fatty acids</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intralipid +/- Omegaven</intervention_name>
    <description>Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.
Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.
Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil).</description>
    <arm_group_label>Intralipid with/without Omegaven</arm_group_label>
    <other_name>Fresenius Kabi, ATC main group B05B A 02</other_name>
    <other_name>Intralipid Vnr 42 79 55</other_name>
    <other_name>Omegaven Vnr 55 25 54</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes defined by clinical criteria and by absence of antibodies to glutamic
             acid decarboxylase.

          -  HbA1c 5,5 - 8,5 %

          -  Blood pressure ≤ 170 mm Hg systolic and/or ≤ 105 mm Hg diastolic

        Exclusion Criteria:

          -  insulin treatment

          -  hypertriglyceridemia (&gt; 2,1 mmol/l TG)

          -  proliferative retinopathy, renal insufficiency (Se-Creatinine &gt; 150 μmol/l)

          -  alcoholism, congestive heart failure or other serious diseases affecting the
             possibility of the subject to participate

          -  supplement with fish oil or marine n-3 fatty acids during the last 6 months before
             baseline

          -  Dicumarol treatment

          -  allergy to soya, fish or egg

          -  pregnancy or lactation

          -  smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valdemar Grill, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Olavs Hospital, NTNU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Division of Endocrinology, St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Mostad IL, Bjerve KS, Basu S, Sutton P, Frayn KN, Grill V. Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus. Metabolism. 2009 Dec;58(12):1753-61. doi: 10.1016/j.metabol.2009.06.003. Epub 2009 Aug 27.</citation>
    <PMID>19716144</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>November 3, 2011</last_update_submitted>
  <last_update_submitted_qc>November 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intralipid</keyword>
  <keyword>Omegaven</keyword>
  <keyword>fish oil</keyword>
  <keyword>hyperinsulinemic isoglycemic clamps</keyword>
  <keyword>C-peptide glucagon test</keyword>
  <keyword>indirect calorimetry</keyword>
  <keyword>F2-isoprostanes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

